Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent
Imagion Biosystems Limited provides medical imaging technologies to detect and eliminate cancer. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company engages in the research and development of its MagSense system to detect HER2 breast cancers. It uses MagSense technology that is based on superparamagnetic relaxometry for early cancer detection, cancer staging, and therapeutic monitoring. The company was founded in 1996 and is based in San Diego, California.